Good Steward Wealth Advisors LLC Purchases Shares of 5,725 Gilead Sciences, Inc. (NASDAQ:GILD)

Good Steward Wealth Advisors LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,725 shares of the biopharmaceutical company's stock, valued at approximately $641,000.

Several other institutional investors have also recently modified their holdings of the stock. Bridgewater Associates LP boosted its stake in shares of Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after acquiring an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its holdings in Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after purchasing an additional 13,086 shares in the last quarter. Mufg Securities Americas Inc. purchased a new position in Gilead Sciences in the 4th quarter valued at about $1,699,000. Finally, JFG Wealth Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $427,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,500 shares of company stock worth $5,236,245. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $0.50 during midday trading on Friday, reaching $108.50. 23,266,621 shares of the company traded hands, compared to its average volume of 7,756,139. The firm has a market capitalization of $134.97 billion, a price-to-earnings ratio of 22.84, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29. The company has a fifty day moving average price of $106.16 and a 200 day moving average price of $102.74. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The company's revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.91%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.